Medicus Pharma Secures Conditional Nasdaq Listing Compliance After Equity Financings
Medicus Pharma (NASDAQ: MDCX) regained Nasdaq listing compliance after raising $4.25 million in equity and exchanging $10.5 million in debt.
Last updated: 2026-11-19 20:59:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Pfizer Inc. (PFE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $27.60, with a market capitalization of $162.27B and a P/E ratio of 40.24. Over the past 52 weeks, its price has ranged from $23.62 to $31.44. This page covers its latest market performance, valuation, price trends and company information.
$162.27B | |
$27.92 | |
$27.99 | |
$27.46 | |
$28.06 | |
28.45M | |
33.47M | |
40.24 | |
$31.44 | |
$23.62 | |
6.03% | |
2026-09-27 |
Pfizer Inc. (PFE) is currently trading at $27.60 as of 2026-11-19 20:42:53, down 2.00% ($0.56) from the previous close of $28.06
During today's regular trading session, PFE has traded between $27.46 and $27.99, with a trading volume of 28.45M shares. The current price is near the lower end of today's range.
Over the past seven days, Pfizer Inc. (PFE) moved from $29.36 to $27.60, representing a decline of 5.98% ($1.76).
The stock traded between $27.46 and $29.77 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 31.81 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 50.9%
PFE is currently trading at $27.60, placing it 50.9% of the way from its 52-week low of $23.62 to its 52-week high of $31.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75,000 |
| CEO | Albert Bourla |
| Founded | 1849 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Pfizer Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 6, 2026 |
| Payment Date | Dec 7, 2026 |
| Dividend Per Share | $0.43 |
Latest news related to Pfizer Inc. and PFE stock.
Medicus Pharma (NASDAQ: MDCX) regained Nasdaq listing compliance after raising $4.25 million in equity and exchanging $10.5 million in debt.
Pfizer is scheduled to pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining an 88-year dividend streak. While the company faces a patent cliff, it has a $14.3 billion cash cushion to support dividends. A combination of three major challenges—patent cliff impact, cash-draining acquisition, and significant clinical setbacks—would likely be needed to end the streak, though analysts view this scenario as unlikely.
The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.
The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.
Pfizer signs up to $2.63B licensing deal with Starna Therapeutics for in vivo CAR-T autoimmune therapies, paying $330M upfront.
Eligible investors can buy real shares of Pfizer Inc. (PFE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PFE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PFE shares and USD.
PFE Shares to USD
1.00 PFE shares = 27.604 USD
Calculations are estimates based on the latest available price and are for reference only.